Pharmicell Co., Ltd.

Research Pharmicell Co., Ltd. (005690.KS) on Bullrun: market cap KRW 652.84B, dividend yield 0.5%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is KRW 652.84B; dividend yield is 0.5%.

Peer valuation comparison

Latest dividend yield is 0.46% versus a Healthcare sector median of 2.4% (80.8% below).

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18KRW 652.84Bn/a0.5%50

Dividend history

Latest trailing dividend snapshot: annual dividend/share 50 KRW, yield 0.5%.

About Pharmicell Co., Ltd.

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells autologous drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC to treat hepatic insufficiency;

Related stock research

South Korea stocks South Korea Healthcare stocks A-Z stock index

Other Healthcare stocks

ORIENT BIO Inc. (002630.KS) GC Corp. (005250.KS) Kanaph Therapeutics Inc. (0082N0.KQ) Samik Pharmaceutical Company LTD. (014950.KQ) HLB Co., Ltd. (028300) Mgen Solutions Co., Ltd. (032790.KQ) Daesung Microbiological Labs. Co., Ltd. (036480.KQ) Seoulin Bioscience Co.,Ltd. (038070.KQ) Hyundai Bioscience Co., Ltd. (048410.KQ) iNtRON Biotechnology, Inc. (048530.KQ) Synergy Innovation Co., Ltd. (048870.KQ) CTCBIO Inc. (060590.KQ)

Frequently asked questions

What is Pharmicell Co., Ltd.'s market cap?

Pharmicell Co., Ltd.'s market capitalization is KRW 652.84B.

Does Pharmicell Co., Ltd. pay a dividend?

Pharmicell Co., Ltd. has a dividend yield of 0.5%.

What does Pharmicell Co., Ltd. do?

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells autologous drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty.